Prokaryotic expression of antimicrobial ovine β- defensin-1 in Escherichia coli by Zhao, P et al.
African Journal of Biotechnology Vol. 10(50), pp. 10212-10217, 5 September, 2011     
Available online at http://www.academicjournals.org/AJB 
DOI: 10.5897/AJB10.2232 
ISSN 1684–5315 © 2011 Academic Journals  
 
 
Full Length Research Paper 
 
Prokaryotic expression of antimicrobial ovine β-
defensin-1 in Escherichia coli 
 
Pengwei Zhao1#, Ruixia Bai2#, Lanling Chen1, Wenbing Hu3, Shiyong Wen1, Yan mi1, Jianrong 




Veterinary College of Inner Mongolia Agricultural University, Hohhot 86-010018, PR China. 
2
Clinical laboratory of Inner Mongulia Hospital PR China. 
3
Animal Science College of Tarim University, Alar, PR China. 
 
Accepted 29 July, 2011 
 
Ovine β-defensin-1 (sBD-1) is a small, cationic peptide, with three canonical cysteine disulfide 
intramolecular bonds. It can inhibit the growth of Gram-positive and Gram-negative bacteria, yeast and 
fungi. We isolated sBD-1 by RT-PCR of small intestinal cDNA. The open reading frame of the cDNA was 
192 bp, which codes 64 amino acids, and the mature peptide of the cDNA was 114bp, which encodes 38 
amino acids. In order to understand their antimicrobial activities, the pre-peptide sBD-1 and the mature 
peptide of sBD-1 were studied. The two proteins were expressed in Escherichia coli. The fusion 
proteins were purified and digested by enterokinase. The digestion products showed that the mature 
peptide can inhibit the growth of E. coli and P.aeruginosa. It will be valuable to produce sBD-1 and 
other defensins for veterinary medical research on antibiotic treatment in ovine production.  
 





Defensins comprise a major subclass of the family of 
antimicrobial peptides. Depending on the size and pairing 
of their six cysteine residues, defensins of higher 
vertebrates are classified as α-, β and θ-defensin (Wang 
et al., 2003). The β-defensins (BD) are characterized by 
six cysteines and have been found in many animal 
species such as bovine (Luenser and Ludwig, 2005), 
ovine (Luenser et al., 2005), porcine and humans 
(Maxwell et al., 2003). BD is produced principally in the 
epithelial cells of a number of organs including skin, lung, 
kidney, pancreas, uterus, eye, and nasal and oral muco-
sa (Klotman and Chang, 2006). In ovine, β-defensin-1 
(sBD-1) is the most prevalent defensin throughout the 
digestive tract with the exception of the distal ileum 
(Huttner, 1998). 
Defensins are a family of small cationic peptides with a 









the growth of fungi,  GRAM-positive,  and  gram-negative 
bacteria, such as Staphylococcus aureus (Hoover, 2000, 
2002), a bacterium that causes infections ranging from 
skin abscesses to life-threatening conditions such as 
endocarditis and toxic shock. In recent years, several 
classes of antimicrobial peptides have been purified from 
mammalian phagocytes (Sawai, 2002). Similar molecules 
have also been isolated from specialized epithelia, sug-
gesting that antimicrobial peptides may play a role in the 
intrinsic resistance of tissues to microbial invasion 
(Morrison, 2002). sBD-1, as an antimicrobial peptide, can 
replace the addition of antibiotics to ovine feed. Recently, 
the antibiotics resistance was hotter and hotter. This 
would be favorable to consumers because it would elimi-
nate residual antibiotics in meat products. sBD-1 
production in vivo shows great promise for veterinary 
medicine. 
Over the past several years, several small cationic 
peptides have been synthesized successfully by 
recombinant gene expression methods (Wu et al., 2003). 
Because of its rapid growth rate and easily established 
protein expression system, Escherichia coli are used as 
the host cell (Hans and Kim, 2005). Many difficulties have  
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been encountered in the expression of genes encoding 
for antimicrobial polypeptides, often times due to their 
cytotoxicity and sensitivity to proteolytic degradation 
(Ganz, 1999, 2004). The fusion strategy (Ma et al., 2009) 
has been utilized in the production of small antimicrobial 
cationic peptides in E. coli to alleviate these problems, 
but fusion proteins tend to form inclusion bodies, which 
leads to inactivation of the expressed proteins (Li et al., 
2004). The E. coli combined translation cell free system 
is popularly used because of its capability to directly 
synthesize protein from an exogenous gene. The system 
can be operated in batch or continuous mode. The batch-
mode method is relatively simple and convenient; 
however, the efficiency of protein synthesis is quite low 
(Martemyanov et al., 1997; Maxwell et al., 2003). 
As a potential therapeutic peptide, the fusion expression 
of sBD-1 has never been reported. In the present study, 
both the pre-peptide sBD-1 (psBD-1) and the mature 
peptide of sBD-1 (msBD-1) were synthesized and 
expressed using an Escherichia coli expression system. 
To improve the production of sBD-1, the conditions of 
cultivation and induction were systematically optimized. 
The fusion protein was purified and cleaved to obtain 
psBD-1 and msBD-1. Antibiotic potentency of the two 
peptides were observed. 
 
 
MATERIALS AND METHODS  
 
Strains, plasmids, and culture medium 
 
E. coli DH5αF’ (TaKaRa, Japan) was cultivated at 37°C in LB 
medium. E. coli BL21 (DE3) was used as the host for the 
expression of heterologous protein. Plasmid pMD19-T Simple 
(TaKaRa, Japan) and pET32a (Novagen, USA) were used as 
cloning and expression vectors, respectively. All restriction 
enzymes and T4 DNA ligase were purchased from TaKaRa, Japan. 
Luria–Bertani (LB) medium (w/v) containing 0.5% yeast extract, 1% 
tryptone and 1% NaCl was used for manipulation of molecular 
clones and seed cultures. 
 
 
The cloning of sBD-1 
 
Total RNA of ovine small intestine was isolated using TRIzol 
reagent (TaKaRa), according to the manufacturer’s 
recommendations, and then treated with RNase-free DNase I 
(TaKaRa). The concentration and purity of RNA were checked by 
absorbance at 260 and 280 nm. 
The cDNA fragment encoding the sBD-1 protein was amplified by 
the reverse transcription polymerase chain reaction (RT-PCR) from 
total RNA, using ExTaq DNA polymerase (TaKaRa) and the 
synthetic oligonucleotide primers sBD-1 (Table 1). DNA 
amplification was conducted with 35 cycles of denaturation (1 min 
at 94°C), annealing (1 min at 59°C), and elongation (2 min at 72°C). 
PCR products were cloned into the PMD19-T simple vector and 
sequenced by TAKARA company. The cloning plasmid was named 
PMD19-T-sBD-1. Nucleotide and deduced amino acid sequence 
comparisons were made using the BLAST (basic local alignment 
search tool) programs BLASTN (Zhang et al., 2000) and BLASTX, 
respectively, on non-redundant nucleotide and protein databases of 
the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/BLAST/). These tools were used to 
deduce the amino acid sequence encoded by the gene sBD-1. 
 
 
Construction of expression vectors 
 
The psBD-1 and msBD-1 cDNAs were amplified by PCR, using 
PMD19-T-sBD-1 as template. Primers are reported in Table1. PCR 
products of psBD-1 and msBD-1 cDNAs were purified and cloned 
between EcoRI and NotI, and NcoI and NotI sites, respectively in 
pET32a vector. The two cloned vectors were transformed into E. 
coli BL21 (DE3). The transformed cells were cultured in LB Broth at 
37°C overnight with shaking at 200 rpm. 500 μl from overnight 
culture was added into 30 ml of fresh LB containing Amp 0.1 mg/ml 
for 1 h until the OD reached 0.4 to 0.6. Then the cells were induced 
by 0.5 mM IPTG. After 5 h incubation, cells were harvested by 
centrifugation at 12000 rpm for 2 min at 4°C. Cells were then 
washed by 1×PBS. Subsequently, the first lysis (prolysis) buffer (20 
mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4, 1 
mMPMSF) was added and mixed to make a homogeneous 
solution. The cells were lysed by sonication at 6× pulse for 8 min on 
ice (20 s pulse on and followed by 10 s pulse off). The cells were 
centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was 
decanted and binding buffer (20 mM sodium phosphate, 0.5 M 
NaCl, 20 mM imidazole, pH 7.4) was added as the 1 ml HisTrap FF 
(GE Healthcare, Sweden). The sample was flowed on binding 
buffer at the rate of 0.5ml/min. After loading the sample, the fusion 
protein was eluted by elution buffer (20 mM sodium phosphate, 0.5 
M NaCl, 500 mM imidazole, pH 7.4). After collection of the fusion 
protein, the inherent buffer in the sample was exchanged for an 
enterokinase buffer (50mM Tris PH7.8, 2mMCaCl2, and 50mM 
NaCl) by gel chromatography using Sephadex G-25. The fusion 
protein was then digested by the enterokinase (NEB, UK) at room 
temperature    for    24 h.   The  digested  sample  was  desalted  by  






Figure 1. Comparison of deduced sBD-1 sequences with ovine BD-2, reindeer BD-1 and porcine. Gene Bank numbers are as 






Figure 2. msBD-1 induced and purified products. 
Lane: 1. purified msBD-1; 2. msBD-1 induction 




Sephadex G-10 with desalting buffer (20mM Tris PH7.8, 
50mCH3COONH4). Finally, the sample was freeze dried.  
The final digestion product was dissolved in 20 mM Tris (pH 7.8), 
to a final concentration of 50 μg/ml. Then, the solution was serially 





Antimicrobial properties of recombinant psBD-1 and msBD-1 were 
tested against sensitive strains of E. coli 44101 and P. aeruginosa 
26003. About 10
6
 colony forming units of P. aeruginosa was 
inoculated into 1 ml M-H medium in the log phase. To deduce the 
optimal concentration of antimicrobial activity, different 
concentrations psBD-1 and msBD-1 were tested (pH 7.8, 25 μg/ml). 
Controls were equivalent volumes of 20 mM Tris buffer. Bacterial 
cultures were shaken for 14 h and concentrations were determined 
by measurement of OD600.  
The inhibitory zone was measured to determine antimicrobial 
activity. 400 μl optimal concentrations of psBD-1 or msBD-1 were 
placed into wells on plated E. coli. The same concentration fusion 






sBD-1 cloning   
 
Based on RT-PCR, a 214bp sBD-1 cDNA was amplified. 
sBD-1 encodes a predicted 64 amino acid protein of 7.2 
kDa with first 26 amino acid residues serving as a signal 
peptide. The mature peptide consists of 38 aa residues of 
about 3.8 KD (Gene Bank number U75250). A BLASTX 
search of the GenBank protein database showed that the 
amino acid sequence has homology with other known 
defensins characterized from different animals with six-
conserved cysteine residues forming three disulfide 
bridges (Figure 1).  
 
 
Construction of expression vectors and prokaryotic 
expression of psBD-1 and msBD-1 fusion proteins  
 
The psBD-1 and msBD-1 proteins from prokaryotic 
expression were purified and characterized. The fusion 
protein yields were not largely affected by increasing or 
reducing the concentration of IPTG. Induction time was 6 
h at 0.5 mM IPTG; and after 6 h, there was no noticeable 
change. Molecular weights of psBD-1 and msBD-1 were 
about 7.2 KDa and 3.8 Kda, respectively. Fusion protein 
molecular weight of psBD-1 and msBD-1 were 24 KDa 
and 20 Kda, respectively. The excess peptide was the tag 
of the pET32 vector. The fusion and purified proteins 
were loaded into SDS-PAGE to determine the purification 




sBD- 1  MRLHHLLLVLFFVVLSAGSGFTQGVRNRLSCHRNKGVCVPSRCPRHMRQI GTCRGPPVKCCRKK  64 
sBD- 2  MRLHHLLLVLFFVVLSAGSGFTHGVTDSLSCRWKKGI CVLTRCPGTMRQI GTCFGPPVKCCRLK  64 
pBD- 1  MRLHRLLLVFLLMVLLPVPGLLKNI GNSVSCLRNKGVCMPGKCAPKMKQI GTCGMPQVKCCKRK  64 
TAP  MRLHHLLLALLFLVLSASSGFTQGVGYPVSCVRNKGI CVPI RCPGNMKQI GTCVGRAVKCCRKK  64 
EBD  MRLHHLLLTLLFLVLSAGSGFTQGI SNPLSCRLNRGI CVPI RCPGNLRQI GTCFTPSVKCCRWR  64 
LAP  MRLHHLLLALLFLVLSAGSGFTQGVRNSQSCRRNKGI CVPI RCPGSMRQI GTCLGAQVKCCRRK  64 


































Figure 3. psBD-1 induced and purified products. 
Lane: 1. psBD-1 induction product; 2. purified 




Cleaving the fusion protein 
 
Fusion proteins were digested by enterokinase; Tricine 
SDS-PAGE was used to detect cleavage. Digestion 





psBD-1 did not show antimicrobial activity, even at high 
concentration (1 mg/ml) (the data was not shown). The 
optimal concentration of msBD-1 against the P. 
aeruginosa was shown by percent inhibition (Table 2). 
The optimal concentration was 96% at 12.5 μg/ml. 
Moreover, inhibition of E. coli by msBD-1 was 





The soluble expression of heterologous proteins in E. coli 
is a good way to obtain the active form of a protein, 
especially proteins with multiple disulfide bridges. Several 
expression systems have been developed by fusing an 
antibiotic peptide with a partner protein or with anionic 
properties to avoid the toxicity of the heterologous protein 
to the host cells and the degradation of the products by 
bacterial proteases (Li et al., 2004; Xiang et al., 2002). 
msBD-1 is a cationic peptide with three disulfide bridges. 
The soluble expression of msBD-1 is an optimal method 
to obtain a bioactive defensin. 
Defensins are positively-charged and contain both 
hydrophobic  and   hydrophilic   domain  peptides  (Ganz,  






Figure 4. msBD-1 and psBD-1 enterokinase digestion products. 




2004). They are among the most potent antimicrobial 
peptides advanced by the mammalian defense system to 
protect against invading pathogens. The antimicrobial 
activity is remarkably specific, with little cytotoxicity to 
mammalian cells even at concentrations ten-fold or 
higher than those required for antimicrobial activity (Kim 
et al., 2003). In ovine, sBD-1 is expressed throughout the 
gastrointestinal tract (Huttner, 1998). This distribution is 
believed to be very beneficial for protecting the body 
invaded by microbes. sBD-1 is mainly expressed in the 
gastrointestinal tract, not in the blood of ovine (Huttner, 
1998). sBD-1 is a key element in the bodies first line of 
defense for ovine. 
Bohling et al. (2006) showed that an α-helix is often 
present at the N-terminus of β-defensins. Because N-
terminal regions are often times aliphatic (Karen et al., 
2008), this region is likely to direct membrane insertion 
and disruption. The msBD-1 showed antimicrobial activity 
while psBD-1 did not. The psBD-1 contains signal 
peptide, and the N-terminal region is likely to be inactive 
and not able to insert and disrupt the microbial 
membrane. The msBD-1 can easily insert and disrupt the 
microbial membrane because an α-helix is present of the 
N-terminal. 
Defensins are at low concentrations active against 
bacteria (Kim et al., 2003). Antimicrobial activity of msBD-
1 was observed at concentrations as low as 12.5 μg/ml, 
which strongly inhibited sensitive strains of E. coli. 
Generally, metabolically active bacteria are much more 
sensitive to defensins than bacteria made inactive by 
nutrient deprivation or metabolic inhibitors. Defensins 
may be the new antimicrobial compounds in the future. 
































Fig. 4. msBD-1 and psBD-1 enterokinase digestion products. Lane: 1. 
msBD-1；2. psBD-1;3. protein marker. 
Lanes: 1. msBD-1; 2. psBD-1; 3. protein marker. 
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Table 2. msBD-1 percent inhibition against P. 
aeruginosa at various concentrations. 
 












Figure 5. The bioactivity of msBD-1 against E. coli. Inhibitory zone test, using E. 
coli. as the sensitive strain: 1. negative control 20-mM Tris (pH 7.8); 2. 10 μg/ml 




produce functional defensins on a large scale and can 
also become a new method to administer antibiotics in 
ovine production, especially meat production. In the 
future, it will be helpful to produce additional defensins for 





In summary, the present study illustrates that msBD-1 
can be successfully expressed and purified from E. coli 
BL21 while retaining their antimicrobial activity. Overall, 
the proposed approach may have potential benefit for the 
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